Abstract
Small interfering RNA (siRNA) has become a specific and powerful tool to turn off the expression of target genes, and has turned into a promising tool in molecular medicine. It can be targeted against cancer by several strategies. These include the suppression of overexpressed oncogenes, retarding cell division by interfering with cyclins and related genes or enhancing apoptosis by inhibiting anti-apoptotic genes. RNA interference (RNAi) against multidrug resistance (MDR) genes or chemo/radio-resistance and angiogenesis targets may also provide beneficial cancer treatments. Successful cancer therapy by siRNA in vitro and in vivo provides the enthusiasm for potential therapeutic applications of this technique. Here, we review RNAi in cancer therapy, highlighting recent progress and examining the hurdles that must be overcome before this promising technology is ready for clinical use.
Keywords: Small interfering RNA, pharmacodynamics, cancer, oncogene, apoptosis, cell cycle, angiogenesis, multidrug resistance, oncogenes, cyclins, anti-apoptotic genes, Carcinogenesis Pathways, Viral Oncogenes, Radiotherapy/Chemotherapy Resistance
Mini-Reviews in Medicinal Chemistry
Title: Small Interfering RNA for Effective Cancer Therapies
Volume: 11 Issue: 2
Author(s): X. Wang, Y. Chen, J. Ren and X. Qu
Affiliation:
Keywords: Small interfering RNA, pharmacodynamics, cancer, oncogene, apoptosis, cell cycle, angiogenesis, multidrug resistance, oncogenes, cyclins, anti-apoptotic genes, Carcinogenesis Pathways, Viral Oncogenes, Radiotherapy/Chemotherapy Resistance
Abstract: Small interfering RNA (siRNA) has become a specific and powerful tool to turn off the expression of target genes, and has turned into a promising tool in molecular medicine. It can be targeted against cancer by several strategies. These include the suppression of overexpressed oncogenes, retarding cell division by interfering with cyclins and related genes or enhancing apoptosis by inhibiting anti-apoptotic genes. RNA interference (RNAi) against multidrug resistance (MDR) genes or chemo/radio-resistance and angiogenesis targets may also provide beneficial cancer treatments. Successful cancer therapy by siRNA in vitro and in vivo provides the enthusiasm for potential therapeutic applications of this technique. Here, we review RNAi in cancer therapy, highlighting recent progress and examining the hurdles that must be overcome before this promising technology is ready for clinical use.
Export Options
About this article
Cite this article as:
Wang X., Chen Y., Ren J. and Qu X., Small Interfering RNA for Effective Cancer Therapies, Mini-Reviews in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/138955711794519528
DOI https://dx.doi.org/10.2174/138955711794519528 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Carbohydrates: Potential Sweet Tools Against Cancer
Current Medicinal Chemistry Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases
Current Medicinal Chemistry Review of the Biological Activity of Maslinic Acid
Current Drug Targets microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Glycoprotein Targeting and Other Applications of Lectins in Biotechnology
Current Protein & Peptide Science Nano-Tetrandrine Efficiently Inhibits the Proliferation and Induces the Apoptosis of Hep2 Cells through a Mitochondrial Signaling Pathway
Current Signal Transduction Therapy Rock1 & 2 Perform Overlapping and Unique Roles in Angiogenesis and Angiosarcoma Tumor Progression
Current Molecular Medicine In vitro Lipolysis: An Indispensable Tool for the Development of IVIVC of Lipid Based Drug Delivery Systems
Drug Delivery Letters Chronic Inflammation and Oxidative Stress as a Major Cause of Age- Related Diseases and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Current Developments for the Diagnosis and Treatment of Irritable Bowel Syndrome
Current Pharmaceutical Design An Update of Radiolabeled Bombesin Analogs for Gastrin-Releasing Peptide Receptor Targeting
Current Pharmaceutical Design Evaluation of Tricine and EDDA as Co-ligands for <sup>99m</sup>Tc-Labeled HYNIC-MSH Analogs for Melanoma Imaging
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Current Diabetes Reviews The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Management of Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Current Immunology Reviews (Discontinued) A Search for Inhibitors of S100B, a Member of the S100 Family of Calcium-Binding Proteins
Mini-Reviews in Medicinal Chemistry Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine
Anti-Cancer Agents in Medicinal Chemistry A Novel 99mTc-labeled Diphosphonic Acid as Potential Bone Seeking Agent: Synthesis and Biological Evaluation
Current Radiopharmaceuticals